Immune Pharmaceuticals Inc. Announces Closing Of P
Post# of 297
| Tuesday, November 25, 2014 3:15 PM |
[PR Newswire] - "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of 3,450,000 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at a price to the public of $2.50 per unit. The warrants will be exercisable for a period of three years following the issuance thereof at an exercise price of $3.75 per a whole share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 517,500 units offered in the public offering to cover over-allotments, if any.
http://us.rd.yahoo.com/finance/news/rss/story...00019.html
~ This Week's OTC News In Review! ~
Covering the entire market and teaching traders! Visit here to learn technicals and fundamentals >>
http://www.stockgoodies.com/lessons.html
~ http://www.fallenheroesfund.org/ ~
St. Jude 2014 Drive has started >> http://tinyurl.com/St-Jude-2014